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Background: Tumour metastasis to the brain is a common and deadly development in certain cancers; 18–30 %
of breast tumours metastasise to the brain. The contribution that gene silencing through epigenetic mechanisms
plays in these metastatic tumours is not well understood.
Results: We have carried out a bioinformatic screen of genome-wide breast tumour methylation data available at
The Cancer Genome Atlas (TCGA) and a broad literature review to identify candidate genes that may contribute
to breast to brain metastasis (BBM). This analysis identified 82 candidates. We investigated the methylation status
of these genes using Combined Bisulfite and Restriction Analysis (CoBRA) and identified 21 genes frequently
methylated in BBM. We have identified three genes, GALNT9, CCDC8 and BNC1, that were frequently methylated
(55, 73 and 71 %, respectively) and silenced in BBM and infrequently methylated in primary breast tumours. CCDC8
was commonly methylated in brain metastases and their associated primary tumours whereas GALNT9 and BNC1
were methylated and silenced only in brain metastases, but not in the associated primary breast tumours from
individual patients. This suggests differing roles for these genes in the evolution of metastatic tumours; CCDC8
methylation occurs at an early stage of metastatic evolution whereas methylation of GANLT9 and BNC1 occurs
at a later stage of tumour evolution. Knockdown of these genes by RNAi resulted in a significant increase in
the migratory and invasive potential of breast cancer cell lines.
Conclusions: These findings indicate that GALNT9 (an initiator of O-glycosylation), CCDC8 (a regulator of microtubule
dynamics) and BNC1 (a transcription factor with a broad range of targets) may play a role in the progression of primary
breast tumours to brain metastases. These genes may be useful as prognostic markers and their products may provide
novel therapeutic targets.
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Brain metastases account for up to 40 % of all secondary
tumours, with an estimated 27,000 new cases every year
in the UK [1, 2]. Current estimates suggest that 18–30 %
of patients with breast cancer eventually develop brain
metastases [3–6]. The frequency of metastatic brain
tumours is rising; this increased incidence is due, in part,
to an ageing population, improved neuroimaging and
increased patient survival following primary tumour treat-
ment [7]. Currently, brain metastases are treated by whole
brain radiotherapy, stereotactic radiosurgery and surgical
resection either individually or in combination [8].
However, following treatment, patient prognosis remains
poor; both morbidity and mortality are high and the
median survival is approximately 7 months [9].
Evidence indicating that tumours originating in specific
organs favour certain sites of metastasis has existed for
over 50 years [10]. However, the underlying mechanisms
of this organotropism towards specific secondary sites
such as the brain are still poorly understood. Although the
genetic basis of primary tumour formation is becoming
increasingly clear [11], it is still unclear which of the many
hundreds of tumour-associated alterations found in
primary breast cancer [12, 13] contribute to metastasis
and moreover, metastasis to specific secondary sites
such as the brain. The primary tumour types that most
frequently metastasise to the brain are lung, breast,
melanoma and renal cancers. However, the speed at which
these secondary tumours develop varies greatly with
breast to brain metastases (BBM) occurring relatively
slowly [7]. This specificity indicates that, at least in part,
genomic alterations that drive tumour formation in these
primary organs provide the potential for colonization of a
distinct subset of secondary organ sites.
There is little in the way of prognostic markers for
BBM. It is known that the risk of BBM occurring early
(<2 years after primary diagnosis) is associated with early
onset tumours, estrogen receptor negative (ER-ve),
human epidermal growth factor receptor 2 overexpression
(HER2 + ve) and triple negative (ER-ve/PR-ve/HER2-ve)
phenotypes [14–17]. However, more than 50 % of BBMs
occur over 5 years after the primary tumour was diagnosed.
Many of these late recurring brain metastases are derived
from ER+ primary tumours [4, 9, 18]. The common long
lag-time between primary tumour diagnosis and recurrence
of a detectable secondary tumour suggests that cells from
these breast tumours undergo a period of dormancy
[19, 20]. These dormant cells are often found as microme-
tastases in bone marrow. However, the presence of these
micrometastases is not in itself a strong prognostic indica-
tor for later metastatic disease [21, 22]. It is possible that
brain micrometastases are common, and these require
further genomic alterations to occur before sustained
proliferation and growth occurs.Genomic alterations that provide the potential for meta-
static growth can be characterised as either those that
also drive primary tumour growth advantage, those
that provide potential for dissemination and infiltration
[23] or those that enable continued growth within the
microenvironment of the new organ [24]. A number
of genetic and epigenetic alterations acquired by breast
tumour micrometastases of the bone have been charac-
terised [25, 26]. However, very little is known about
specific genomic alterations that facilitate colonisation
in the brain.
We have carried out a screen to identify genes frequently
dysregulated through promoter hypermethylation in BBM.
This analysis has identified candidate genes that are either
dysregulated early in tumour evolution (methylation is
common to primary tumour and resulting BBM) or at a
later stage, once the cells that will evolve into the BBM have
disseminated from the primary tumour. We hope that this
preliminary analysis may provide initial evidence of
novel targets that can be utilised in the development of
prognostic screens and new rational therapeutic approaches
for breast tumours and brain metastases.
Methods
Selection of candidate metastatic suppressor genes
For an overview of our candidate selection strategies see
Additional file 1: Figure S1. We utilized the Illumina
HumanMethylation 450 K BeadChip methylation array
data from The Cancer Genome Atlas (TCGA) to identify
candidate genes (Additional file 2: Table S1 for TCGA
tumour barcodes). To ensure we were selecting genuine
promoter-associated CpG islands, we selected only those
probes that are located in the 5′ region of the gene or
up to 1500 base pairs from the transcription start site
(identified in the array annotation as TSS, TSS200,
TSS1500). We identified individual probes that are not
methylated (β value ≤ 0.25) in 75 % (15/20) of primary
breast tumours and methylated (β value ≥ 0.60) in primary
lung tumours, in at least 50 % (10/20) of the samples.
This analysis generated four candidates that were then
characterised in the laboratory.
In addition to our bioinformatic analysis, we carried
out a broad literature review to identify candidate
genes. We generated a long-list of genes that had pre-
viously been identified as hypermethylated in one of
the primary tumours types that readily metastasise to
the brain (lung, melanoma or renal [7]). We expanded this
long-list by selecting genes that are downregulated in
epithelial-mesenchymal transition (EMT) and that
possess a well-defined promoter region CpG island.
By interrogating all the available breast tumour methyla-
tion data in the TCGA by using their data portal
(https://tcga-data.nci.nih.gov/tcga/), we shortlisted only
those genes that were infrequently methylated in primary
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were then characterised in the laboratory.
Patients and samples
Thirty-one fresh-frozen metastatic brain tumours ori-
ginating from primary breast tumours were provided
by The Walton Research Tissue Bank, Liverpool and Brain
Tumour North West (BTNW) Tissue Bank, Preston.
Eleven pairs of formalin fixed paraffin embedded (FFPE)
primary breast tumours corresponding to matched
metastatic brain tumours were provided by BTNW
tissue bank. Receptor status information is available
for 9 of the 11 primary tumour pairs, six of these are
ER + ve, one is triple negative. The time between primary
tumour surgery and removal of the brain metastasis
ranges from 2 to 10 years (Additional file 3: Table S2a).
A cohort of 40 independent primary breast tumours
was also analysed. All breast tumours from this cohort
were ducal carcinomas; their clinical characteristics are
described in [27]. Molecular characterisation was available
for 20 of these tumours, 15 of these are ER + ve and three
are triple negative. No brain metastases were observed in
any of these patients, nine patients had been screened
for metastasis 10 years or more post-primary tumour
surgery and 17 of the 20 after more than 5 years
(Additional file 3: Table S2b).
Tissues were obtained from National research Ethics
committee approved research tissue banks, and informed
consent was obtained from each patient. This study was
conducted according to the principles expressed in the
Declaration of Helsinki.
Breast cancer cell Lines and 5-Aza-2′–deoxycytidine
treatment
Five breast cancer cell lines (MCF7, T74D, MDA-MB231,
BT549 and ZR75) were routinely maintained in DMEM
(Sigma, UK) supplemented with 10 % FCS at 37 °C and 5 %
CO2. Cells were plated according to their doubling time to
ensure that both control and 5-AZA-2′-deoxycytidine
(5-AZA-dC; Sigma, UK)-treated cells lines were approxi-
mately 75 % confluent at the time of RNA extraction.
5-AZA-dC was freshly prepared in ddH2O and filter
sterilized. Twenty-four hours after seeding, cells were
treated with 5 μM 5-AZA-dC. Cells were treated with
fresh 5 μM 5-AZA-dC three times a week on alternate days.
After 7 days, the cells were collected using 1 % trypsin; cell
pellets were washed with PBS.
Genomic DNA/RNA extraction
Genomic DNA was extracted from fresh-frozen metastatic
brain tumours using The DNA isolation kit from cells and
tissues (Roche, Germany). Briefly, 25 mg of tissue was
homogenised using lysis buffer and incubated at 37 °C
for 30 min followed by addition of Proteinase K andRNase solution. The samples were then centrifuged and
processed according to manufacturer’s instructions. For
FFPE samples, a FFPE DNA extraction kit (Qiagen, USA)
was used. Briefly, a small block of samples embedded with
paraffin was cut into thin sections and mixed with xylene
followed by 100 % ethanol. The samples were then proc-
essed according to manufacturer’s instructions. Similarly,
total RNA was extracted using the EZ-RNA extraction kit
(Biological Industries, Israel). Briefly, fresh-frozen tumours
were homogenized using lysis buffer followed by addition
of extraction solution. The samples were then centrifuged
and processed according to manufacturer’s instructions.
DNA concentration was measured using a nanodrop2000
(Thermo Scientific, USA).
Bisulfite conversion of DNA
Bisulfite conversion of genomic DNA from metastatic
brain tumours (500 ng) and positive controls was carried
out using the EZ DNA methylation kit (Zymo Research
Corp., USA) according to manufacturer’s instruction. Fully
methylated, positive controls were generated by incubating
gDNA with DNA methyltransferase, in the presence of
S-Adenosyl methionine (SAM) (New England bio lab, USA)
for 2 h at 37 °C prior to bisulfite conversion.
Promoter methylation analysis
Primers used to amplify promoter regions from bisulfite-
modified DNA can be found in Additional file 4: Table S3.
Primers were designed based on standard bisulfite DNA
primer designing criteria [28]. These primers were used to
amplify bisulfite converted DNA. DNA methylation was de-
termined by digesting Combined Bisulfite and Restriction
Analysis (CoBRA) PCR products with the BstUI and TaqI
restriction enzymes (Fementas, UK).
Quantitative methylation analysis of tumour DNA was
carried out by cloning bisulfite-PCR products (individual
alleles) into pGEM plasmid (Promega, UK) followed by
sequencing of individual clones using primers to M13.
The CpG island regions of BNC1, CCDC8 and GALNT9
are presented in Additional file 5: Figure S2, details of PCR
primer sites and individual CpG dinucleotides analysed by
sequencing are provided.
Migration assay
Candidate genes were knocked down in breast cancer
cell lines by transfection of RNAi ‘silencer select’ oligos
against CCDC8 (s228331), BNC1 (s2012) or GALNT9
(s27040), control cells were transfected with control
oligo no. 1 (Ambion, Austin, TX, USA). After 24 h,
DMEM with 10 % FBS was replaced with fresh DMEM
without FBS and incubated at 37 °C for 24 h. Confluent
monolayer of cells in each well was scratched with the
tip of a 200 μl pipette tip. The extent of migration of
cells was observed after 24 and 48 h.
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Two hundred microlitres of matrigel matrix (Becton
Dickinson, NJ, USA) was applied to 24-well 9-mm inserts
containing polyethylene terephthalate (PET) membranes
with 8-um pores (Corning, USA). One hundred fifty
thousand cells were applied to the invasion chamber.
DMEM containing 10 % FBS was placed in the lower
chamber as a chemoattractant. The plates were incubated
at 37 °C for 48 h with 5 % CO2. Cells from the lower layer
were stained with crystal violet. The optical density at
540 nm for each well was determined.
Western blotting
Cells were lysed in RIPA buffer (25 mM HCL, 0.1 %
SDS, 1 % triton 100, 0.15 M NaCl) containing phosphatase
and protease inhibitor (Roche, Germany). Seventy micro-
grams of each extract was resolved on polyacrylamide gels
and probed with anti-rabbit primary antibody against
CCDC8 (ab170233), BNC1 (ab123645) or GALNT9
(ab173682) (Abcam, USA). Signals were detected with
horseradish peroxidase-conjugated anti-rabbit antibody
(GE Healthcare, UK) and enhanced chemiluminescence
(Biological Industries, Israel). Membranes were stained
with India ink (Winsor and Newton, UK) for comparison
of loading.
Results
Screening of candidate BBM suppressor genes
We have used a candidate gene approach to identify
genes deregulated in breast tumours that metastasise
to the brain. See Additional file 6: Table S4 for details
of genes.
Bioinformatic analysis of primary tumour genome-wide
methylation arrays identified four candidate BBM
suppressor genes
We have compared the methylation status (β value) of
array probes in TCGA data sets from 20 primary breast
tumours (with no evidence of metastatic disease) and
20 primary lung tumours. We hypothesised that genes
that are infrequently methylated in non-metastasising
breast tumours and frequently methylated in primary
lung tumours that readily metastasis to the brain
(metastases are identified relatively soon after primary
tumour diagnosis) [29] may be commonly methylated
in metastatic brain tumours that derive from both lung
and breast tumours.
We filtered probes in primary breast tumours to
identify those that are infrequently methylated, (having a
β value ≤ 0.25 in at least 15/20 (75 %)). This resulted
in 97,155 probes. Filtering of frequently methylated
probes, (having a β value ≥ 0.60 in at least 50 % (10/20)) in
lung tumours resulted in 45,382 probes. Comparison of
the probes between breast and lung tumours identifiedeight probes that corresponded to six genes (GALNT9,
KRT222, PLEKHA6, TFAP2A, TSPAN4 and ZNF808).
Two of these genes (KRT222 and PLEKHA6) do not have
well-defined CpG islands. In total, this genome wide
approach identified four candidate genes (GALNT9,
TFAP2A, TSPAN4 and ZNF808) for further analysis.
A literature review identified 78 candidates BBM
suppressor genes
We have screened genes that have previously been
shown to be frequently methylated and silenced in at
least one of the primary tumours types that rapidly
(relative to many breast tumours) metastasise to the
brain, i.e. lung, melanoma and renal cell carcinoma
(RCC) [7]. We then interrogated TCGA to determine the
methylation status of these genes in primary breast
tumours. This screen identified 42 candidate meta-
static suppressor genes that are infrequently methylated
in primary breast cancer and frequently methylated in pri-
mary lung, melanoma or renal tumours (Additional file 6:
Table S4 and references therein).
In addition, we selected 36 metastasis suppressor candi-
dates that are downregulated during EMT (Additional file 6:
Table S4 and references therein).
Identification of frequently methylated genes in
metastatic brain tumours
The methylation status of 82 candidate genes was de-
termined by CoBRA [28] in 30 BBM. To ensure that
we were identifying genes which are enriched in the
population of patients with BBM that are most likely
to be clinically significant, we have imposed a high
cut-off of ≥50 % of all metastatic tumours being
methylated for a gene to be considered as frequently
methylated. For this preliminary screening, we have deter-
mined that a significant proportion of the promoters
within the tumour sample is methylated if there are clearly
observed digest products following restriction analysis.
From the panel of four genes selected from our
analyses of HumanMethylation 450 K BeadChip arrays
obtained from TCGA, only one gene, GALNT9, was
frequently methylated (55 %) in metastatic brain tumours
originating from primary breast tumours (see Table 1,
Fig. 1a, Additional file 7: Figure S3).
From our panel of 42 literature review candidate genes,
we identified ten genes that are frequently methylated
in brain metastases. These were HOXD3 (100 %),
CCDC8 (73 %), HOXB13 (80 %), ABCB1 (80 %),
PENK (80 %), BNC1 (71 %), PCDH8 (53 %), STAT3
(67 %), TNFRSF10D (60 %) and WIF1 (53 %) (see Table 1,
Fig. 1a, Additional file 7: Figure S3).
We proceeded to determine the methylation status of
these ten genes in an independent cohort of primary
breast tumours.
Table 1 Genes frequently methylated in breast to brain metastases. Twenty-one genes are frequently methylated in brain
metastases (n = 15) of which 18 genes are also frequently methylated in primary breast tumours (n = 20). Three genes, CCDC8,
BNC1 and GALNT9 (highlighted in grey), are infrequently methylated in primary breast tumours. These genes were further analysed
in 20 primary breast samples (n = 40 in total) and 15 breast to brain metastases (n = 30 in total)
Gene symbol Accession Gene name % of metastatic
tumours methylated
Function
CLDN18 NM_016369.3 Claudin 18 100 Intercellular adhesion molecule responsible for tight
junction strand formation [77]
KRT85 NM_002283.3 Keratin 85 100 Component of intermediate filament in epithelial cells
contributing to cell-cell adhesion [78–80]
MIR127 NR_029696.1 microRNA 127 100 Regulator of cell proliferation and senescence [81]
MIR433 NR_029966.1 microRNA 433 100 Deregulated in gastric cancer, regulator of cell migration
and drug response [82, 83]
HOXD3 NM_006898.4 HomeoboxD3 100 Proangiogenic transcription factor [84]
MIR23B NR_029664.1 microRNA 23b 92 Involved in cytoskeleton modelling, motility and
metastasis [85–88]
CCDC8 NM_032040.4 Coil coiled domain containing 8 73 Mutated in patients with 3 M syndrome [70]. Loss is
associated with genomic instability and aneuploidy [75].
KRT83 NM_002282.3 Keratin 83 84 Component of intermediate filament, contributes to cell
to cell adhesion [78, 80]
HOXB13 NM_006361.5 Homeobox B13 80 TSG for prostate cancer, inhibits androgen mediated
signalling [89]
ABCB1 NM_000927.4 ATP-binding cassette
sub-family B member 1
80 Controls efflux of substances across plasma membranes,
associated with multidrug resistance [90]
PENK NM_006211.3 Proenkephalin 80 Promotes RNA splicing in osteoblasts and neural
cells, plays role in bone development [91]
MST1R NM_002447.2 Macrophage stimulating
1 receptor
78 Involved in intracellular signalling cascades leading to
cellular growth, motility and invasion [92]
BNC1 NM_001717.3 Basonuclin 1 71 Zink finger transcription factor, regulator of EMT [68]
PCDH8 NM_002590.3 Procadhern 8 73 Helps in cell to cell adhesion [93]
STAT3 NM_139276.2 Signal transducer and
activator of transcription 3
67 Involved in embryonic stem cell regulation, somatic cell
growth [94–96]
BVES NM_007073.4 Blood vessel epicardial substance 64 Involved in inter-cellular interaction and cell adhesion [97]
TNFRSF10D NM_003840.4 Tumour Necrosis Factor
receptor superfamily 10 D
60 Member of TNF (Tumour Necrosis Factor) receptor
superfamily, promotes apoptosis in cancer cells [98]
CLDN6 NM_021195.4 Claudin 6 55 Intercellular adhesion molecules responsible for tight
junction strand formation, its epigenetic silencing is
associated with migration and invasiveness of breast
cancer [77, 99]
HOXD10 NM_002148.3 Homeobox D10 55 Maintain epithelial cell plasticity and contributes to
stability of extracellular matrix [100]
GALNT9 NM_001122636.1 N-acetyl galactosaminyl
transferase 9
55 Catalyzes O-glycosylation [53, 101]
WIF1 NM_007191.4 Wnt inhibitory factor-1 gene 53 Inhibitor of Wnt-signalling [102, 103]
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in EMT, we identified 10 genes frequently methylated in
metastatic brain tumours originated from primary breast
tumours. These were CLDN18 (100 %), KRT85 (100 %),
MIR127 (100 %), MIR433 (100 %), MIR23b (92 %),
KRT83 (84 %), MST1R (78 %), BVES (64 %), CLDN6
(55 %) and HOXD10 (55 %) (see Table 1, Fig. 1a). We
proceeded to determine the methylation status of these
ten genes in an independent cohort of primary breast
tumours.A graphical overview of our candidate selection
process and results is presented in Additional file 1:
Figure S1.
GALNT9, BNC1 and CCDC8 are differentially methylated in
primary breast tumours and BBM
We have screened primary breast tumours for the pres-
ence of methylation in the genes that are frequently
methylated in BBM. To ensure that genes identified in
this study are clinically significant, we have imposed a
Fig. 1 (See legend on next page.)
Pangeni et al. Clinical Epigenetics  (2015) 7:57 Page 6 of 17
(See figure on previous page.)
Fig. 1 a Methylation frequency of candidate metastatic suppressor genes in breast-to-brain metastases (BBM) (n = 30) versus primary breast
tumours (n = 40). Out of the 25 genes that were frequently methylated in brain metastases, three genes (GALNT9, CCDC8 and BNC1) were
infrequently methylated in a cohort of independent primary tumours with statistical significance (p = 0.0001, 0.01 and 0.0001, respectively).
b, c Expression of GALNT9, CCDC8 and BNC1 correlates with promoter methylation in BBM. Reverse transcription PCR (RT-PCR) for GALNT9,
CCDC8 and BNC1 in BBM shows that these genes were expressed in tumours where their promoters are unmethylated (U) and silenced in
methylated (M) tumours (see Additional file 7: Figs S3 and Additional file 9: Figure S5 for representative methylation analysis). Expression of
β-actin was determined to ensure equal loading for all samples. c Expression levels of each gene were quantified in relation to the expression
of β-actin. The methylation status was determined by either CoBRA or sequencing of individual alleles to determine the methylation index
(MI) for individual tumours. High levels of expression were not associated with high levels of methylation in the region analysed. A full set of methylation/
expression analysis can be seen in Additional file 10: Figure S6 (BM brain metastasis, M methylated, U unmethylated, − analysis was not done)
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in primary breast tumours.
We analysed the 21 genes that were frequently methylated
in BBM in a cohort of 40 primary breast tumours (unrelated
to the brain metastasis cohort [27]).
We found GALNT9 to be frequently methylated in
BBM (55 %) and not methylated in any of the 40 primary
breast tumours (p = 0.0001).
From a panel of ten genes frequently methylated in
brain metastases (from our literature review candidates),
we identified that eight of these genes were also frequently
methylated in primary breast tumours. These are HOXD3
(81 %), HOXB13 (53 %), ABCB1 (68 %), PCDH8 (54 %),
PENK (79 %), STAT3 (57 %),TNFRSF10D (75 %) andWIFI
(55 %) (Fig. 1a). This suggests that these genes are not
uniquely epigenetically deregulated during the process of
BBM. However, it is worth noting that to our knowledge
this is the first time that promoter methylation in CCDC8,
HOXD3, PCDH8, PENK, STAT3, SFRP2 and WIFI has
been described in primary breast tumours.
Promoter methylation of BNC1 (17 %) and CCDC8
(40 %) in primary breast tumours was infrequent (≤45 %),
and statistically significantly lower than that of the
frequency of methylation in BBM (p = 0.0001 and
0.01, respectively) (Fig. 1a). The low frequency of
methylation in primary tumours indicates that BNC1 and
CCDC8 may contribute to BBM and are good candidates
for further investigation.
We found that all ten EMT-related genes were frequently
methylated in primary breast tumours, i.e. CLDN18
(100 %), KRT85 (100 %), MIR127 (100 %),MIR433 (100 %),
MIR23b (60 %), KRT83 (100 %), MST1R (60 %), BVES
(60 %), CLDN6 (50 %) and HOXD10 (55 %) (Fig. 1a). The
high frequency of methylation in primary tumours
indicates that epigenetic deregulation of these genes is not
driving BBM.
From our broad-ranging screens, we have identified
GALNT9, BNC1 and CCDC8 as frequently methylated in
BBM and significantly less frequently methylated in primary
breast tumours (Fig. 1, Additional file 8: Figure S4).
To ensure that CoBRA digests were representative of
high methylation status in tumours, we carried out base-
resolution analysis of promoter region methylation forBNC1, CCDC8 and GALNT9 by cloning and sequencing
individual bisulfite-modified alleles from select tumours
(Additional file 9: Figure S5). This analysis was used
to determine the methylation index (MI) of CpG
islands for individual tumours. MI is defined as the
total number of methylated CpG dinucleotides given as a
percentage of all CpGs analysed. The MI for regions
determined to be methylated by CoBRA ranged from
60 to 91 % whereas those promoters deemed not to
be methylated by CoBRA had MIs ranging between 0 and
36 %. From this analysis, we have defined that, for these
samples, physiologically significant methylation levels are
those of ≥60 % MI and lack of physiologically significant
methylation is defined as <40 % MI.
Expression analysis of BNC1, CCDC8 and GALNT9 in
metastatic brain tumours
Having identified three candidate genes that are differen-
tially methylated in primary breast tumours and metastatic
brain tumours, we proceeded to determine if this promoter
methylation correlated to gene expression.
Total RNA was extracted from 15 metastatic brain
tumours to determine the expression of BNC1, CCDC8
and GALNT9 by RT-PCR. The expression level of each
gene was quantified in relation to the expression of
β-actin, in tumours with unmethylated promoters
(MI = 0–25 %). The maximum expression of these
genes was 49, 23 and 33 % that of β-actin, respectively.
BNC1, CCDC8 and GALNT9 were frequently downregu-
lated or silenced in these tumours and reduced expression
correlated to promoter methylation as determined by
CoBRA and base-resolution sequencing (Fig. 1b and c,
Additional file 10: Figure S6). These genes were also
commonly silenced in breast cancer cell lines, this
silencing was reversed following treatment with 5-Aza-
2′-deoxycytidine an inhibitor of DNA methyltransferase
enzymes [30] (Additional file 11: Figure S7).
Promoter methylation status of BNC1, CCDC8 and GALNT9
in brain metastases and associated primary breast
tumours from individual patients
We analysed the methylation status BNC1, CCDC8 and
GALNT9 in metastatic brain tumours and corresponding
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pairs, however, some loci in the primary tumour DNA
proved refractive to amplification. Of eight matched
pairs, where the BNC1 promoter region was successfully
amplified, the region was methylated in all eight of the
brain metastases. However, it was only methylated in oneFig. 2 Methylation status of GALNT9, CCDC8 and BNC1 in metastatic brain t
from individual patients. CoBRA was used to determine methylation status;
the undigested (U) lane indicates promoter methylation in a sample. a GAL
brain tumours (BM). However, GALNT9 and BNC1 were not commonly meth
promoter was methylated in both the originating primary tumours (BP) an
eight matched pairs analysed, BNC1 was methylated in all metastatic brain
primary tumours (for example, see patients 2, 3 and 8). Of six matched pair
(see patients 1 and 12), whereas it was not methylated in any of the corres
methylated in ten metastatic tumours and all corresponding primary tumo
methylated in normal tissue (BN) adjacent to the primary breast tumour (se
BN adjacent normal breast tissue, U uncut/control sample, C cut by methylcorresponding primary tumour (Fig. 2a). The GALNT9
promoter was methylated in 3/5 brain metastases and not
methylated in any of the corresponding primary breast
tumours (Fig. 2b). In contrast, out of 11 matched pairs,
CCDC8 was commonly methylated in 10 correspond-
ing primary tumours (Fig. 2c). This common CCDC8umours and their corresponding originating primary breast tumours
small, digested PCR products in the Bstu1 cut (C) lane compared to
NT9, b CCDC8 and c BNC1 were frequently methylated (*) in metastatic
ylated in the originating breast primary (BP) tumours (a, c). CCDC8
d the associated brain metastases (BM) from individual patients (b). Of
tumours whereas it was methylated in only one of the corresponding
s analysed, GALNT9 was methylated in three metastatic brain tumours
ponding primary tumours. Of 11 matched pairs analysed, CCDC8 was
urs (for example, see patients 1, 3 and 5). However, it was not
e patient 1). (BP breast primary tumour, BM metastatic brain tumour,
ation specific restriction enzyme, *methylated samples)
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metastasis was confirmed by sequencing individual alleles
for pairs of tumours from two patients (patient 11 and 15
(BM11, Primary BT 11 and BM15, Primary BT 15)). Both
primary tumour DNA and BM DNA were found to have
MIs above 73 % (Additional file 9: Figure S5a).
These results suggest that BNC1 and GALNT9 pro-
moter methylation occurs at a late stage in the evolution
of metastatic brain tumours, possibly after they have
metastasised to the brain. Alternatively, methylation of
these genes may occur in a small subset of cells within
the primary tumour (below the detection threshold of
this assay), and these cells are enriched in the metastatic
tumour. In contrast, CCDC8 promoter methylation is
detectable in most primary tumours that metastasise to
the brain, suggesting that it may play an important role
in the early stages of primary tumour metastasis.
Loss of GALNT9, CCDC8 or BNC1 expression increases
metastatic potential
We have identified that CCDC8 is dysregulated at an early
point of BBM, and its promoter methylation is detectable
in the primary tumours that proceed to metastases.
GALNT9 and BNC1 methylation is uncommon in primaryFig. 3 Loss of CCDC8, BNC1 or GALNT9 expression increases the migratory
expressed CCDC8, BNC1 or GALNT9 were identified; the expression of these
and Additonal file 12: Fig. S8). a T47D cell lines transfected with siRNA olig
against BNC1 or c MDA-MB231 cell lines transfected with siRNA against GA
lines transfected with control siRNA oligos. Following siRNA transfection, conf
was scratched through them (0 h). Forty eight hours later the distance migrat
from the initial would. The distance migrated (in percentage) by respective ce
compared to the respective cell lines transfected with control siRNA oligos wbreast tumours and is often not detectable in the tumours
that metastasise. These differences suggest that loss of
these genes confers metastatic potential though alter-
native mechanisms. However, loss of BNC1 or CCDC8
expression has previously been shown to increase the
clonagenic potential of RCC cell lines [31, 32]. Loss
of GALNT9 has yet to be directly linked with increased
malignancy. We have investigated the effect that loss of
these genes has on metastasis-related properties of breast
cancer cell lines.Loss of GALNT9, CCDC8 or BNC1 expression increases
breast cancer cell line cell motility
Forty-eight hours after initial transfection with siRNA
oligos against BNC1, CCDC8 or GALNT9 breast cancer
cell lines showed loss of specific gene expression
(Additional file 12: Figure S8).
In a wound-healing assay, knockdown of these genes
increased migratory potential compared to cell lines
transfected with control oligos. The increase in motility of
cell lines following knockdown of BNC1 (Fig. 3a), CCDC8
(Fig. 3b) or GALNT9 (Fig. 3c) was statistically significant
compared to control cells (scrambled siRNA transfected)potential of breast cancer cell lines. Breast cancer cell lines that
genes was knocked down by siRNA (see Additional file 11: Figure S7
os against CCDC8; b MCF7 cell lines transfected with siRNA oligos
LNT9 exhibited more migratory potential compared to respective cell
luent cells were incubated in serum-free media and an artificial wound
ed was calculated by subtracting the value of non-migrated distance
ll lines knocked down with siRNA against CCDC8, BNC1 or GALNT9 in
as statistically significant (p = 0.001, 0.011 and 0.027, respectively)
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All experiments were repeated in triplicate.
Reduced expression of GALNT9, CCDC8 or BNC1 increases
invasive potential
GALNT9, BNC1 and CCDC8 were knocked down in breast
cancer cell lines by siRNA and applied to matrigel-coated
invasion chambers as described in the methods.
Forty-eight hours later, cells that had ‘invaded’ were
isolated and quantified.
Following knockdown of GALNT9, 35 % more cells
invaded (p = 0.025) compared to cell transfected with the
control scrambled siRNA (Fig. 4a). Following knockdown
of CCDC8, 27 % more cells invaded, (p = 0.021) (Fig. 4b).
The number of breast cancer cell that invaded following
BNC1 knocked down was increased by 40 % (p = 0.006)
(Fig. 4c).
Increased motility and invasive potential following re-
duction of expression of these genes suggests that these
candidates may be involved in the regulation of normal
cellular physiology and that loss of their expression may
contribute the metastatic process.
Reduced expression of GALNT9 or CCDC8 is significantly
associated with poor relapse-free survival
The clinical significance of the expression of BNC1,
CCDC8 and GALNT9 was analysed using publically
available GEO expression profiles using the prognoscan
database [33]. Prognoscan partitions a patient population
into high-expressor and low-expressor group for each
gene by choosing a threshold that maximises the statis-
tical significance of difference in outcome. It corrects
for multiple testing using the method of Miller and
Siegmund [34]. In two independent datasets, low CCDC8
expression was significantly associated with poor relapse
free survival (GSE12276, p = 0.001; GSE1456-GPL97,
p = 0.004) (Fig. 5a), and in one data set, low GALNT9
expression was associated with poor relapse free survival,
(GSE1379, p = 0.0029) (Fig. 5b). There was no evidence in
any of the datasets analysed that low BNC1 expression
correlated with poor relapse free survival or any other
clinical indicator.
Discussion
Given the extremely poor clinical outcome following a
diagnosis of BBM [9], it is imperative that the underlying
molecular biology that drives tumour evolution to the
colonization of the brain is elucidated.
To date, some progress has been made to identify
prognostic markers for breast cancer metastasis by
gene expression profiling [35]. However, prediction of
site-specific metastasis remains poor [36].
The importance of gene dysregulation by promoter
methylation as a mechanism of tumour evolution is nowwell established [37]. Indeed, genome wide methylation
analysis of many hundreds of primary breast tumours
has allowed the definition of specific sub-categories of
breast tumours [12, 13], and our increasing understanding
of the molecular basis of these subtypes has improved our
ability to predict early metastatic recurrence [14, 38].
However, late recurrence, a common feature of BBM has
proven difficult to predict [39].
We have carried out a broad candidate approach
to identify genes that are dysregulated in BBM
(Additional file 1: Figure S1). This analysis has identi-
fied three genes (BNC1, CCDC8 and GALNT9) that
are differentially methylated in primary breast tumours
and BBM.
We predicted that our analysis of unrelated primary
breast tumours and BBM would identify two different
classes of genes that contribute to BBM, epigenetic si-
lencing of BBM associated genes would either occur
as (i) early events in tumour evolution that may be
involved in processes such as local invasion and intra-
vasion [40, 41] or these early events may be required
for specific distant site metastasis but also contribute
to primary tumour development or (ii) late events
that play no significant role in the initial evolution of
the primary tumour but contribute to the development of
the secondary brain metastasis, perhaps by improving the
capacity of these cells to survive in the foreign micro-
environment of the brain.
The existence of early and late events had previously
been proposed by Nguyen et al. [42], they classified
deregulated genes as either involved in (i) metastasis
initiation, detectable in the primary tumour, (ii) metastasis
progression genes, important for survival in the circulation
or required for extravasation, while occasionally present
in the primary tumour, they may also occur once metasta-
sising cells have left the primary site, or (iii) metastasis
virulence genes that allow the cancer cells to survive in a
foreign tissue environment. These are likely to occur as a
consequence of the selection pressure provided by the
novel environment the metastasised tumour cells find
themselves in. Metastasis progression genes may have
different functions in the primary tumour and distant
metastasis, for example, MMP-1 promotes vascular re-
modelling in primary breast tumours and also contributes
to lung extravasation [43]. An example of a known metas-
tasis virulence genes that does not contribute to primary
tumour growth is interleukin-11, which promotes breast
tumour metastasis to the bone but does not provide any
advantage to the primary tumour [44].
Both early and late methylation events will appear
similarly in our initial analysis; the genes will be fre-
quently methylated in BBM and infrequently methylated
in unrelated primary breast tumours, this is the case
for BNC1, CCDC8 and GALNT9 (Fig. 1). However, a
Fig. 4 (See legend on next page.)
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Fig. 4 Reduced expression of GALNT9, CCDC8 or BNC1 increases the invasive potential of breast cancer cell lines. Trans-well invasion assays were
carried out following the knockdown of of GALNT9, CCDC8 or BNC1 in breast cancer cell lines. The invasive capacity of these cells was compared
with the same cell lines transfected with control siRNA oligos (control). The numbers of cells that had invaded a matrigel-coated micropore
membrane was determined colourimetrically 48 h after initial seeding. a MDA-MB231 cell lines transfected with siRNA oligos against GALNT9,
b T47D cell lines transfected with siRNA oligos against CCDC8 and c MCF7 cell lines transfected with siRNA oligos against BNC1 exhibited a
statistically significant increase in invasiveness compared to negative control siRNA transfected cells. p = 0.025 (GALNT9), p = 0.021 (CCDC8)
and p = 0.001 (BNC1). Invasive potential was calculated as a percentage increase above that observed for the control cells (% invasion)
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same patient should reveal if specific gene methylation
occurs early or late in the process of tumour evolution.
Our analysis of such tumour pairs (Fig. 2) identified that
BNC1 and GALNT9 are not frequently methylated in any
breast tumours, even those that will eventually develop
into brain metastases where these genes are methylated.
Their methylation appears to be a late event in tumour
evolution/metastasis. However, the CCDC8 promoter
was commonly methylated in primary breast tumoursFig. 5 Loss of expression of CCDC8 and GALNT9 correlates with relapse-free
studies via the prognoscan database revealed that in two separate studies
associated with poor relapse free survivalthat eventually develop brain metastases and as such it
can be categorised as an early event in tumour evolution/
metastasis.
GALNT9 encodes a member of the UDP-N-acetyl-
α-D-galactosamine:polypeptide N-acetylgalactosaminyl-
transferase family of enzymes that catalyze the first step
of O-glycosylation; GALNAC-T9. GLANT9 is expressed
most abundantly in the brain and other CNS tissues. It is
also expressed, at lower levels, in a number of other
tissues including normal breast (GeneCards) [45].patient survival. Kaplan–Meier analysis of multiple gene expression
low expression of a CCDC8 (p = 0.001) and b GALNT9 (p = 0.003) was
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glycosylation in the golgi apparatus by the covalent linkage
of an α-N-acetylgalactosamine (GalNAc) to Ser and Thr
residues [46]. O-Glycans play an important role in cell
adhesion and cell-cell communication, and dysregulated
glycosylation is a common characteristic of tumour cells
[47]. Mucin 1 (MUC1), in particular, has been identified
as a highly O-glycosylated transmembrane protein that is
dysregulated at the expression and posttranslational
level in multiple tumour types [47]. MUC1 is commonly
overexpressed but under-glycosylated in primary breast
tumours [48, 49], and the expression of under-glycosylated
MUC1 is associated with high tumour grade, metastatic po-
tential and invasiveness of breast tumours [50–52]. Loss of
GALNT9 expression in neuroblastoma has been linked to
a highly malignant phenotype and associated with poor
overall and disease free survival [53]. GALNT9 is a member
of a sub family (with GALNT8, 18 and 19) that differ
significantly in sequence from other GALNAC-T members
[54] and as such does not have catalytic activity towards
classic MUC1 variants derivatives [55, 56]. This suggests
that GALNT9 glycosylates a specific group of substrates
indicating a subtle regulation of transmembrane protein
function. Our findings of GALNT9 promoter methylation,
and associated loss of expression, in BBM, but not in
primary breast tumours suggest that this change in
transmembrane protein function may be a common
occurrence in the later stages of breast tumour brain
metastasis, and perhaps relates to cell-cell interaction that
the tumour cells must undergo before acquiring a suitable
niche to proliferate within the novel microenvironment of
the brain.
This is the first time that GLANT9 has been shown to be
dysregulated in cancer by promoter methylation. However,
conserved mutations have been identified in approximately
2 % of microsatellite instable colorectal cancers [57]
and GALNT9 is also mutated, infrequently (<1 %), in
astrocytoma [58] and lung tumours [59, 60] and infre-
quently lost through CNV in breast tumours [12, 60].
Basonuclin 1 (BNC1) is a zinc finger transcription
factor that interacts with the promoters of both RNA
polymerases I and II [61]. BNC1 target genes have
been implicated in a broad range of functions includ-
ing chromatin structure, transcription/DNA-binding,
adhesion, signal transduction and intracellular transport
[61–63]. It is expressed in a broad range of tissue types
(GeneCards) [45].
BNC1 has previously been shown to be silenced by
promoter methylation in lung [64], renal [31], pancreatic
[65], prostate [66] and leukemic cancers [67]. In vitro assays
have shown that loss of BNC1 expression is associated with
an increased malignant phenotype [31]. Consistent with
this study, analysis of HumanMethylation 27 and 450 K
array data from The Cancer Genome Atlas indicates thatBNC1 Promoter methylation is an infrequent event in
primary breast tumours [12]. However, frequent BNC1
promoter methylation (>60 %) in a small cohort of breast
tumours has previously been reported [64].
The expression of BNC1 is induced by transforming
growth factor-β1 signalling and, in turn, it acts as a
transcription factor for a number of modulators of
epithelial dedifferentiation during EMT [68]. Moreover,
loss of BNC1 expression results in a reduced EMT pheno-
type. These findings suggest that the expression of BNC1
would enhance the process of metastasis via EMT. Our
findings are consistent with this; we find that BNC1 is
infrequently methylated in primary breast tumours (17 %)
and frequently methylated and silenced in BBMs (73 %).
Moreover, we have shown that BNC1 promoter methyla-
tion is a late event in tumour evolution, only occurring in
the brain metastasis of a BBM patient and not in the associ-
ated primary tumour. It is plausible that BNC1 expression
is commonly required for EMT to occur during metastasis
and, once these cells have metastasised to the brain, loss of
BNC1 expression contributes to mesenchymal to epithelial
transition (MET).
An in vitro screen that consisted of multiple rounds of
breast cancer cell line injection into nude mice and recul-
turing of the resulting brain metastases showed that
BNC1 was among a large number of genes overexpressed
in mouse brain metastases [69]. This apparent difference
to our findings may be as a consequence of the model
used. Alternatively, it may represent important differences
in the process of aggressive early metastasis (as cell line
injection models represent) and slower metastatic evolu-
tion, where tumour cells proceed through a phase of
latency or micrometastasis. Many of the brain metastases
in our study were identified several years after initial
breast cancer diagnosis (Paired primary and BBM samples
were excised between 2 and 10 years apart).
CCDC8 encodes a coiled-coil domain containing
protein (CCDC8) that is one of three proteins that are
mutated in patients with 3 M syndrome [70], an auto-
somal recessive disorder characterised by short stature,
skeletal abnormalities, reduced male hormone and blood
vessel bulges [71–73]. CCDC8 is mutated in ~5 % of 3 M
cases, the other genes, CUL7 and OBSL1 are mutated
in ~65 % and ~30 % of cases, respectively [70, 74].
These three proteins form a complex (the 3 M complex)
and loss of expression of any one protein disrupts
microtubule dynamics resulting in dysregulated mitosis,
cytokinesis, associated genomic instability and aneuploidy
[75]. Moreover, it was shown that loss of any 3 M complex
protein significantly altered the interphase microtubule
network [75]. The core 3 M-protein complex interacts with
CUL9, which has been proposed to mediate the functions
of the 3 M complex via the ubiquitylation and degradation
of survivin [76]. The 3 M-complex also interacts with the F
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p53 [75] suggesting it may contribute to correct cellular
physiology through multiple mechanisms.
Despite the broad range and very different known
functions that these three proteins have it is interesting to
see that, at the level of in vitro assays, reduced expression
of any of them increases metastatic potential (Figs. 3, 4).
Conclusions
Our findings indicate that epigenetic dysregulation of
GALNT9, CCDC8 or BNC1 in breast tumours may
contribute to metastasis to the brain and possibly other
distant organs. CCDC8 dysregulation occurs early during
tumour evolution, in addition to being a potential thera-
peutic target this early inactivation has the potential to be
utilised as a prognostic biomarker. Further analysis will be
required including studies to determine if such epigenetic
markers can be discerned via non-invasive means such as
analysis of circulating tumour material in the patients
blood. GALNT9 and BNC1 promoter methylation and
associated silencing is common in BBM but does not
occur frequently in the originating breast tumours
suggesting that their dysregulation may not necessarily
benefit the primary tumour but are required for successful
colonization of the brain. Further studies will be required
to determine if these changes are detectable in circulating
tumour cells, micrometastases, or only in macroscopic
brain metastases. Our current understanding of the cellular
function of these genes is far from complete. However,
what is known about all three suggests that their dysregula-
tion may be more that just a marker for BBM. As such
these genes may represent novel therapeutic targets.
Additional files
Additional file 1: Figure S1. Graphical overview of methodologies
used and results obtained in this study. (A) A literature review was
carried out to identify genes that are methylated in lung, melanoma
and renal cancer as these often metastasise to the brain rapidly. If these
genes were not known to be frequently methylated in breast tumours
(that metastasise to the brain with a longer lag period) they were
considered as good candidates. (B) A literature review was carried out
to identify genes down regulated in Epithelial to Mesenchmal Transition
(EMT). (C) Analysis of genome-wide methylation data from The Cancer
Genome Atlas identified 4 genes frequently methylated in Lung tumours
and infrequently methylated in breast tumours with no evidence of
distant metastasis. Genes from these candidate lists were screened for
methylation in breast to brain metastases (BBM), those that were frequently
methylated were then screened for methylation in non-metastatic primary
breast tumours. Of the 82 genes analysed BNC1, CCDC8 and GALNT9
were frequently methylated in BBM and infrequently methylated in
non-metastatic primary breast tumours, suggesting a role in the evolution
of metastatic tumours.
Additional file 2: Table S1. TCGA tumour barcodes: Unique barcode of
Breast Invasive Carcinoma (BRCA) and Lung Adenocarcinoma (LUAD)
tumours from The Cancer Genome Atlas (TCGA) downloaded for
bioinformatic analysis to screen for candidate genes, which may
contribute to breast to brain metastases (BBM).Additional file 3: Table S2. Molecular characteristics and other clinical
information relating to primary breast tumours analyzed in this study.
(A) Primary breast tumours that have metastasised to the brain. These
primary tumours have associated metastases analysed in this study.
(B) Primary breast tumours with no evidence of metastasis to the
brain. These patients have no evidence of developing brain metastases,
see Methods: Patients and samples for further details (N: Negative,
P: Positive; 0: Negative, 1: Positive).
Additional file 4: Table S3. Primers used in CoBRA and
Reverse-Transcription (RT) PCR. CoBRA (Combined Bisulphite and
Restriction Analysis) primers were designed to amplify promoter
regions of 82 genes In addition, RT primers were designed to
amplify transcripts of BNC1, CCDC8 and GALNT9 to investigate their
expression in breast cancer cell lines and breast to brain metastases.
F: Forward primer, IF: Internal Forward primer, IR: Internal Reverse
primer, R: Reverse primer.
Additional file 5: Figure S2. The promoter region/CpG islands of BNC1,
CCDC8 and GALNT9. The region amplified for CoBRA analysis is found
between the Internal Forward primer and the Reverse primer. CpG
dinucleotides are highlighted in bold. CpG dinucleotides analysed by
cloning and sequencing of individual alleles are numbered. An arrow
indicates the transcription start site.
Additional file 6: Table S4. Genes analysed for their methylation status
in breast to brain metastases (BBM) and their function. Methylation status
of CpG island promoter region of 82 genes (4 genes from our
bioinformatic screen and 78 genes from a broad literature review
including genes down regulated in Epithelial- Mesenchymal Transition)
was interrogated using Combined Bisulphite and Restriction Analysis
(CoBRA) in BBM (n=15). 21 genes were frequently methylated in BBM
(light grey background) of which, 3 genes (CCDC8, BNC1 and GALNT9)
(dark grey background) were infrequently methylated in an independent
cohort of primary tumours (n=15). These three genes were further analysed in
20 more primary breast samples (n=30 in total) and 15 more BBM (n=30).
Additional file 7: Figure S3. Methylation analysis of BNC1, CCDC8 and
GALNT9 in Breast to brain metastases. Up to 31 brain metastases (BM)
were analysed by CoBRA, small, digested PCR products in the Bstu1
cut (C) lane compared to the undigested (U) lane indicates promoter
methylation in a sample (SAM DNA: genomic DNA treated with
S-Adenosyl methionine and DNA methyltransferase as a positive control).
Additional file 8: Figure S4. Methylation status of GALNT9, CCDC8 and
BNC1 in metastatic brain tumours from primary breast tumours and a
cohort of unrelated primary breast tumours. (A) GALNT9 was frequently
methylated in metastatic brain tumours (55 %) and (B) was NOT
methylated in any of the primary tumours; (C) CCDC8 was frequently
methylated in metastatic brain tumours (73 %) and (D) infrequently
methylated in primary breast tumours (40 %). (E) BNC1 is frequently
methylated in metastatic brain tumours 68 % and (F) infrequently
methylated in a cohort of unrelated primary breast tumours (17 %). We
have determined that a significant proportion of the promoters within
the tumour sample are methylated if there are clearly observed digest
products following restriction analysis BM: Brain metastases, BP: Primary
breast tumours, U: Uncut/control sample, C: cut by restriction enzyme,
*: methylated samples).
Additional file 9: Figure S5. Bisulphite sequencing of individual alleles
form tumours. Tumours were analysed by cloning and sequencing
bisulphite-PCR products to determine the extent of methylation within
the region analysed by CoBRA. 10 clones/alleles were sequenced for
each tumour and the methylation index (MI) for each tumour determined.
(A) Tumours that were determined to have significant CCDC8 promoter
methylation by CoBRA (BM11, BM15, BM12 and BM14) had methylation
indices ranging from 66 %-90 %. The corresponding primary breast tumours
for BM11 and BM15 were also analyses these both had correspondingly
high MIs (82 % and 74 % respectively). Tumours that had no evidence of
CCDC8 promoter region methylation by CoBRA analysis (BM16, BM23) had
low MIs (8 % and 6 % respectively). (B) Tumours that were determined to
have significant BNC1 promoter methylation by CoBRA (BM13, BM14, BM15
and BM27) had methylation indices ranging from 60 %-86 %. Tumours that
had no evidence of BNC1 promoter region methylation by CoBRA analysis
Pangeni et al. Clinical Epigenetics  (2015) 7:57 Page 15 of 17(BM11, BM23) had low MIs (0 % and 36 % respectively). (C) Tumours that
were determined to have significant GALNT9 promoter methylation by
CoBRA (BM12, BM20, BM27 and BM28) had methylation indices ranging
from 78 %-91 %. Tumour BM23 that had no evidence of GALNT9 promoter
region methylation by CoBRA analysis had a low MI (25 %). Each circle
represents a CpG island, those shaded black are methylated. MI is
defended as the total number of methylated CpG dinucleotides given
as a percentage of all CpGs analysed.
Additional file 10: Figure S6. Expression levels of BNC1. CCDC8 and
GALNT9 in all tumours analysed. The expression level of each gene was
quantified in relation to the expression of β-actin. Below each bar is the
methylation status of each CpG island as determined by CoBRA and
sequencing of individual alleles (MI) (BM: Brain Metastasis, MI: Methylation
index, M: Methylated, U: Unmethylated, -: analysis was not done).
Additional file 11: Figure S7. Global demethylation resulted in the
re-expression of GALNT9, CCDC8 and BNC1 in breast cancer cell lines. Re-
verse transcription PCR (RT-PCR) showed that treatment of breast
cancer cell lines with 5- 2-deoxycytidine (5-AZA-dC), an inhibitor of DNA
methyltransferase enzymes, resulted in re-expression of (A) GALNT9, (B)
CCDC8 or (C) BNC1 in the breast cancer cell line ZR75. For comparison,
endogenous expression is shown in (A) MDA-MD231, (B) T47D and (C)
MCF7, these, expressing, cell lines were used in our in vitro knock down
experiments.
Additional file 12: Figure S8. Knockdown of GALNT9, CCDC8, and BNC1
in breast cancer cell lines is confirmed by Reverse transcription (RT) PCR
and western blot. (A) RT-PCR of GALNT9, CCDC8, and BNC1 transcripts in
breast cancer cell lines (MDA-MD231, T47D and MCF7 respectively)
following siRNA knockdown compared to transfection with a control
siRNA and (B) western blot of GALNT9, CCDC8, and BNC1 proteins to
confirm their knockdown in each respective cell line. 70 μg of protein
was loaded in each lane. Equal loading was confirmed by staining total
protein with India ink.
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